Disease or Syndrome
Johnson & Johnson Expands into IL-13 and TSLP Market with Strategic Acquisition
Johnson & Johnson, I&I acquisition, IL-13, TSLP, competitive market, strategic expansion, pharmaceutical industry, biologics, inflammatory diseases.
WHO Negotiations Extended for Global Pandemic Agreement
World Health Organization (WHO), pandemic accord, international agreement, global health, deadline, negotiations, public health emergency, disease outbreaks.
FDA Imposes Three-Month Delay on Ascendis’ Hypoparathyroidism Treatment
Ascendis Pharma, hypoparathyroidism, FDA, drug approval, delay, three-month setback, regulatory hurdle, treatment, endocrine disorder.
Beyond Weight Loss: Wegovy’s Cardiovascular Benefits Uncovered in New Study
Wegovy, cardiovascular benefits, weight loss, GLP-1 receptor agonist, heart health, obesity treatment, diabetes management, clinical study.
FDA Rejects Dynavax’s Heplisav-B Expansion Due to Data Gaps
FDA, Dynavax, Heplisav-B, data gaps, rejection, expansion, vaccine, hepatitis B
Revolutionizing Pharmaceuticals: Nabla Bio Secures $26M for AI-Powered Protein Design
Nabla Bio, generative AI, protein design, funding, pharmaceutical partners, biotechnology, drug discovery.
Novo Nordisk’s Wegovy Shines as a Promising Obesity Treatment: A 4-Year Analysis
Novo Nordisk, Wegovy, obesity treatment, weight loss, 4-year data, clinical trials, blockbuster drug, GLP-1 receptor agonist, FDA approval, semaglutide.
Novo Nordisk’s Wegovy Demonstrates Long-Term Weight Loss Success in New Analysis
Novo Nordisk, Wegovy, weight loss, long-term, four years, analysis, obesity treatment, semaglutide, sustained weight loss, diabetes, cardiovascular disease.
Cytokinetics’ Phase III Trials Show Promise in Challenging Cardiomyopathy Treatment Dominated by BMS
Cytokinetics, Phase III trials, cardiomyopathy, Bristol-Myers Squibb (BMS), heart failure treatment, myosin inhibitors, omecamtiv mecarbil, clinical data, heart muscle contraction, cardiovascular disease.
Cytokinetics Unveils Aficamten Data, Gears Up for Market Competition Against Camzyos
Cytokinetics, Aficamten, Camzyos, clinical data, cardiovascular disease, myotonic dystrophy, heart failure, commercial strategy, market competition.